FAQ 1. What is pulsed field ablation (PFA), and how does it work?
PFA is a nonthermal ablation modality that delivers microsecond-scale, high-voltage electrical pulses to create lesions via irreversible electroporation—disrupting cardiomyocyte membranes and triggering cell death without relying on heat or freezing.1 In contemporary atrial fibrillation (AF) ablation technology, this mechanism is associated with rapid lesion delivery and potentially more tissue selectivity than thermal energy, supporting interest in EP lab innovation.1,2 Clinical trials in AF show that PFA can achieve effective pulmonary vein isolation (PVI) with outcomes comparable to conventional thermal approaches in appropriate populations.3,4
FAQ 2. How does the safety profile of PFA compare with thermal AF ablation?
Across major studies, PFA has shown a favorable safety profile consistent with its nonthermal mechanism. In a randomized trial in paroxysmal AF, PFA was noninferior to conventional thermal ablation with low rates of serious adverse events.3 Large- scale real-world data from the MANIFEST-17K study demonstrated low rates of serious adverse events across more than 17,000 PFA procedures, supporting a favorable safety profile for PFA in routine electrophysiology (EP) practice.5 That said, EP teams should recognize that rare but clinically relevant adverse events have been reported, with hemolysis and associated acute kidney injury observed in some clinical series, underscoring the importance of procedural protocols and mitigation strategies.2
FAQ 3. Where does PFA fit in EP practice today?
Today, PFA is best supported as a PVI-first strategy, particularly for drug-refractory paroxysmal AF, with evidence demonstrating outcomes comparable to conventional thermal ablation.3 In prospective pivotal data that included paroxysmal and persistent cohorts, PFA achieved strong procedural performance and clinically meaningful rhythm outcomes, reinforcing its role as a mainstream EP option rather than an experimental tool.4 In contemporary practice, many EP laboratories are incorporating PFA into existing ablation workflows for selected AF populations, while ongoing studies continue to define its role in persistent AF.1
FAQ 4. What are the workflow implications for EP lab teams adopting PFA ablation?
From a workflow standpoint, PFA can reduce time spent on point-by-point lesion creation because energy delivery is rapid, and PVI can often be achieved efficiently with contemporary PFA catheter designs.3,4 In clinical studies comparing PFA with conventional thermal ablation, total procedure and left atrial dwell times have been significantly shorter with PFA, suggesting potential procedural efficiency benefits.6 As with any novel ablation technology, clinical experience and procedural standardization are evolving, and continued evaluation of technique and outcomes is emphasized as PFA is incorporated into broader clinical practice.1,3
FAQ 5. What key uncertainties and safety considerations remain as PFA use expands?
Despite rapid adoption, some uncertainties remain. Contemporary reviews emphasize that PFA is not a single uniform technology, with differences in waveforms, catheter designs, and energy delivery parameters that may influence lesion formation and observed outcomes.1 Long-term data on lesion durability, performance in persistent AF, and outcomes beyond PVI continue to evolve.1,3
In addition, recent clinical reports have described hemolysis with associated acute kidney injury following PFA in a subset of patients, highlighting a safety consideration that appears related to procedural factors such as postablation hydration and the number of PFA applications delivered.2 Their recognition highlights the value of continued post-market surveillance as PFA technology and clinical experience continue to evolve.
References
- Chun KRJ, Miklavčič D, Vlachos K, et al. State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective. Europace. 2024;26(6):euae134. doi:10.1093/europace/euae134
- Mohanty S, Casella M, Compagnucci P, et al. Acute kidney injury resulting from hemoglobinuria after pulsed-field ablation in atrial fibrillation: is it preventable? JACC Clin Electrophysiol. 2024;10(4):709-715. doi:10.1016/j.jacep.2023.12.008
- Reddy VY, Gerstenfeld EP, Natale A, et al; ADVENT Investigators. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med. 2023;389(18):1660-1671. doi:10.1056/NEJMoa2307291
- Verma A, Haines DE, Boersma LV, et al; PULSED AF Investigators. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF Pivotal Trial. Circulation. 2023;147(19):1422-1432. doi:10.1161/CIRCULATIONAHA.123.063988
- Ekanem E, Neuzil P, Reichlin T, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med. 2024;30(7):2020-2029. doi:10.1038/s41591-024-03114-3
- Mohsen J, Nasra C, Neven K, et al. Pulsed-field ablation significantly shortens procedural and left atrial dwell times compared to cryoballoon and radiofrequency pulmonary vein isolation ablation in a meta-analysis of 12 studies. EP Europace. 2025;27(Suppl_1):euaf085.346. doi:10.1093/europace/euaf085.346